Exacerbations of severe asthma in patients treated with mepolizumab

Rahul Shrimanker, Ian D Pavord, Steve Yancey, Liam G Heaney, Ruth H Green, Peter Bradding, Beverley Hargadon, Chris E Brightling, Andrew J Wardlaw, Pranabashis Haldar

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Mepolizumab, a humanised monoclonal antibody that neutralises interleukin-5, reduces exacerbations of severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD) [1, 2]. The beneficial effect of treatment is most obvious in patients with a raised peripheral blood eosinophil count, a group who are at high risk of exacerbation off treatment [2, 3]. Even in this population, exacerbation rates whilst receiving mepolizumab are around one per patient per year. The nature of these remaining exacerbations has not been described. We carried out a post hoc comparison of exacerbations occurring during treatment with mepolizumab or placebo in a previously reported, double-blind, placebo-controlled trial of mepolizumab in severe eosinophilic asthma [1]. We tested the hypothesis that exacerbations in each group differ with respect to change in symptom scores, forced expiratory volume in 1 s (FEV1) and inflammatory profile.
Original languageEnglish
JournalEuropean Respiratory Journal
Issue number6
Publication statusPublished - 13 Dec 2018


  • Anti-Asthmatic Agents/administration & dosage
  • Antibodies, Monoclonal, Humanized/administration & dosage
  • Asthma/diagnosis
  • Disease Progression
  • Double-Blind Method
  • Humans
  • Treatment Outcome


Dive into the research topics of 'Exacerbations of severe asthma in patients treated with mepolizumab'. Together they form a unique fingerprint.

Cite this